Related Experiment Video
Updated: Oct 16, 2025

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research
Alejandro Plana1, Brian Furner2, Monica Palese1
1Department of Pediatrics, University of Chicago, Chicago, IL.
Insights
Building the Pediatric Cancer Data Commons (PCDC) is crucial for advancing pediatric cancer research. This initiative establishes a robust data ecosystem to improve outcomes for children with cancer.
Area of Science:
- Oncology
- Bioinformatics
- Data Science
Background:
- International pediatric oncology research collaboration is well-established.
- The US Children's Cancer Data Initiative (2019) emphasizes pediatric oncology data ecosystem development.
- The Pediatric Cancer Data Commons (PCDC) builds upon this by creating a data resource for children's cancers.
Purpose of the Study:
- To present the experience of constructing the PCDC.
- To highlight the significance of data commons in fighting pediatric cancer and improving outcomes.
- To provide a blueprint for developing similar resources in other disease areas.
Main Methods:
- Identified six critical features for data commons design and implementation.
- Focused on establishing need, technical infrastructure, governance, user-friendliness, community engagement, and sustainability.
- Integrated high-quality clinical and phenotype data with external sources like genomic, proteomic, and imaging data.
Main Results:
- Six critical features for successful data commons were identified.
- The PCDC aims to facilitate research on large patient cohorts.
- Connecting diverse data types (clinical, genomic, imaging) is valuable.
Conclusions:
- Data commons are essential for advancing pediatric cancer research and improving patient outcomes.
- The PCDC framework offers a scalable model for other clinical areas.
- Future PCDC steps include fostering data-sharing culture, standardizing data, and incorporating advanced analytics.
Abstract:
The international pediatric oncology community has a long history of research collaboration. In the United States, the 2019 launch of the Children's Cancer Data Initiative puts the focus on developing a rich and robust data ecosystem for pediatric oncology. In this spirit, we present here our experience in constructing the Pediatric Cancer Data Commons (PCDC) to highlight the significance of this effort in fighting pediatric cancer and improving outcomes and to provide essential information to those creating resources in other disease areas. The University of Chicago's PCDC team has worked with the international research community since 2015 to build data commons for children's cancers. We identified six critical features of successful data commons design and implementation: (1) establish the need for a data commons, (2) develop and deploy the technical infrastructure, (3) establish and implement governance, (4) make the data commons platform easy and intuitive for researchers, (5) socialize the data commons and create working knowledge and expertise in the research community, and (6) plan for longevity and sustainability. Data commons are critical to conducting research on large patient cohorts that will ultimately lead to improved outcomes for children with cancer. There is value in connecting high-quality clinical and phenotype data to external sources of data such as genomic, proteomics, and imaging data. Next steps for the PCDC include creating an informed and invested data-sharing culture, developing sustainable methods of data collection and sharing, standardizing genetic biomarker reporting, incorporating radiologic and molecular analysis data, and building models for electronic patient consent. The methods and processes described here can be extended to any clinical area and provide a blueprint for others wishing to develop similar resources.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Excretion
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

